- Home
- LYFT vs NUVL Comparison
LYFT vs NUVL Comparison
Compare LYFT & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYFT
- NUVL
- Stock Information
- Founded
- LYFT 2007
- NUVL 2017
- Country
- LYFT United States
- NUVL United States
- Employees
- LYFT N/A
- NUVL N/A
- Industry
- LYFT Business Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- LYFT Consumer Discretionary
- NUVL Health Care
- Exchange
- LYFT Nasdaq
- NUVL Nasdaq
- Market Cap
- LYFT 6.3B
- NUVL 5.8B
- IPO Year
- LYFT 2019
- NUVL 2021
- Fundamental
- Price
- LYFT $14.58
- NUVL $78.24
- Analyst Decision
- LYFT Buy
- NUVL Strong Buy
- Analyst Count
- LYFT 31
- NUVL 10
- Target Price
- LYFT $16.98
- NUVL $119.60
- AVG Volume (30 Days)
- LYFT 18.9M
- NUVL 497.2K
- Earning Date
- LYFT 08-06-2025
- NUVL 08-07-2025
- Dividend Yield
- LYFT N/A
- NUVL N/A
- EPS Growth
- LYFT N/A
- NUVL N/A
- EPS
- LYFT 0.22
- NUVL N/A
- Revenue
- LYFT $6,111,324,000.00
- NUVL N/A
- Revenue This Year
- LYFT $13.91
- NUVL N/A
- Revenue Next Year
- LYFT $12.99
- NUVL N/A
- P/E Ratio
- LYFT $65.88
- NUVL N/A
- Revenue Growth
- LYFT 19.94
- NUVL N/A
- 52 Week Low
- LYFT $9.66
- NUVL $55.54
- 52 Week High
- LYFT $19.07
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- LYFT 52.16
- NUVL 49.70
- Support Level
- LYFT $13.17
- NUVL $71.13
- Resistance Level
- LYFT $14.67
- NUVL $80.15
- Average True Range (ATR)
- LYFT 0.52
- NUVL 3.18
- MACD
- LYFT 0.03
- NUVL -0.41
- Stochastic Oscillator
- LYFT 94.02
- NUVL 57.50
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.